Vivani Medical Files 8-K

Ticker: VANI · Form: 8-K · Filed: Sep 4, 2025 · CIK: 1266806

Sentiment: neutral

Topics: 8-K, corporate-filing, financial-statements

TL;DR

Vivani Medical filed an 8-K on Sept 4, 2025, reporting other events and financials.

AI Summary

Vivani Medical, Inc. filed an 8-K on September 4, 2025, reporting other events and financial statements. The company, formerly known as Second Sight Medical Products Inc., is incorporated in Delaware and headquartered in Alameda, California.

Why It Matters

This filing indicates Vivani Medical is providing updates on its corporate activities and financial status to the SEC.

Risk Assessment

Risk Level: low — This is a routine filing reporting corporate events and financial statements, not indicating immediate financial distress or significant new risks.

Key Numbers

Key Players & Entities

FAQ

What specific 'Other Events' are being reported by Vivani Medical, Inc. in this 8-K filing?

The filing indicates 'Other Events' are being reported, but the specific details of these events are not provided in the provided text snippet.

When was Vivani Medical, Inc. formerly known as Second Sight Medical Products Inc.?

The date of the name change from Second Sight Medical Products Inc. to Vivani Medical, Inc. is not specified in the provided text, only that it is the former name.

What is the Standard Industrial Classification (SIC) code for Vivani Medical, Inc.?

The SIC code for Vivani Medical, Inc. is 3845, which corresponds to ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS.

In which state is Vivani Medical, Inc. incorporated?

Vivani Medical, Inc. is incorporated in Delaware.

What is the fiscal year end for Vivani Medical, Inc.?

The fiscal year end for Vivani Medical, Inc. is December 31 (1231).

Filing Stats: 471 words · 2 min read · ~2 pages · Grade level 10.3 · Accepted 2025-09-04 16:56:03

Key Financial Figures

Filing Documents

01 Other Events

Item 8.01 Other Events. On September 4 , 202 5 , Vivani Medical, Inc. (the "Company") announced clinical development plans for NPM -139, the Company's investigational semaglutide implant for chronic weight management in patients who are either obese and overweight with a related comorbidity . A copy of the press release issued in connection with this announcement is being furnished as Exhibit 99.1 to this Current Report on Form 8-K.

Financial Statements and Exhibits

Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99. 1 Press release issued by Vivani Medical, Inc. on September 4 , 202 5. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. VIVANI MEDICAL, INC. Date: September 4 , 202 5 By: /s/ Donald Dwyer Name: Donald Dwyer Title: Chief Business Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing